DK0696280T3 - Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister - Google Patents

Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister

Info

Publication number: DK0696280T3
Authority: DK; Denmark
Prior art keywords: alkyl; tachykinin antagonists; substituted pyrrolidin; piperidines; useful
Prior art date: 1993-05-06

Application number

DK94917898.2T

Other languages

English (en)

Inventor

Timothy P Burkholder

Tieu-Binh Le

Elizabeth M Kudlacz

George D Maynard

Original Assignee

Merrell Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-06

Filing date

1994-04-22

Publication date

1998-01-12

1994-04-22 Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc

1998-01-12 Application granted granted Critical

1998-01-12 Publication of DK0696280T3 publication Critical patent/DK0696280T3/da

Links

102000003141 Tachykinin Human genes 0.000 title abstract 3
108060008037 tachykinin Proteins 0.000 title abstract 3
239000005557 antagonist Substances 0.000 title 1
230000008485 antagonism Effects 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
101800000399 Neurokinin A Proteins 0.000 abstract 1
102400000097 Neurokinin A Human genes 0.000 abstract 1
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 abstract 1
102100024304 Protachykinin-1 Human genes 0.000 abstract 1
101800003906 Substance P Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

DK94917898.2T 1993-05-06 1994-04-22 Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister DK0696280T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US5860693A	1993-05-06	1993-05-06
US21848394A	1994-03-28	1994-03-28
US22537194A	1994-04-19	1994-04-19

Publications (1)

Publication Number	Publication Date
DK0696280T3 true DK0696280T3 (da)	1998-01-12

Family

ID=27369482

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94917898.2T DK0696280T3 (da)	1993-05-06	1994-04-22	Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister

Country Status (18)

Country	Link
EP (1)	EP0696280B1 (da)
JP (1)	JP3424174B2 (da)
CN (1)	CN1081635C (da)
AT (1)	ATE158580T1 (da)
AU (1)	AU678023B2 (da)
CA (1)	CA2160462C (da)
DE (1)	DE69405862T2 (da)
DK (1)	DK0696280T3 (da)
ES (1)	ES2110761T3 (da)
FI (1)	FI113047B (da)
GR (1)	GR3025475T3 (da)
HU (1)	HU224496B1 (da)
IL (1)	IL109496A (da)
MX (1)	MX9403386A (da)
NO (1)	NO309144B1 (da)
NZ (1)	NZ267209A (da)
TW (1)	TW281675B (da)
WO (1)	WO1994026735A1 (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2717802B1 (fr) *	1994-03-25	1996-06-21	Sanofi Sa	Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
CN1067385C (zh)	1994-08-25	2001-06-20	默里尔药物公司	用于治疗变应性疾病的新的取代的哌啶类化合物
CA2162786A1 (en) *	1994-11-22	1996-05-23	Philip Arthur Hipskind	Heterocyclic tachykinin receptor antagonists
FR2728165A1 (fr) *	1994-12-19	1996-06-21	Oreal	Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) *	1994-12-19	1996-06-21	Oreal	Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2729954B1 (fr) *	1995-01-30	1997-08-01	Sanofi Sa	Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
HUP9702149A3 (en) *	1995-03-15	1999-07-28	Aventis Pharmaceuticals Inc Br	Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
NZ306022A (en) *	1995-04-13	1998-09-24	Hoechst Marion Roussel Inc	Phenyl, naphthyl or indolyl substituted piperazine derivatives and medicaments
US5661163A (en) *	1995-06-07	1997-08-26	Merck & Co., Inc.	Alpha-1a adrenergic receptor antagonists
FR2738245B1 (fr) *	1995-08-28	1997-11-21	Sanofi Sa	Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
FR2738819B1 (fr) *	1995-09-14	1997-12-05	Sanofi Sa	Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
JP3041051B2 (ja) *	1995-10-10	2000-05-15	ファイザー・インコーポレーテッド	遺伝子治療における神経性炎症の予防のためのｎｋ−１レセプターアンタゴニスト
US6211199B1 (en)	1995-11-17	2001-04-03	Aventis Pharmaceuticals Inc.	Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
RU2135494C1 (ru) *	1995-12-01	1999-08-27	Санкио Компани Лимитед	Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
US6423704B2 (en)	1995-12-20	2002-07-23	Aventis Pharmaceuticals Inc.	Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en)	1995-12-20	2001-02-27	Aventis Pharmaceuticals Inc.	Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
WO1997022604A1 (en) *	1995-12-20	1997-06-26	Hoechst Marion Roussel, Inc.	Novel substituted 4-(1h-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
GB9600235D0 (en)	1996-01-05	1996-03-06	Pfizer Ltd	Therapeutic agents
US5932571A (en) *	1996-02-21	1999-08-03	Hoechst Marion Roussel, Inc.	Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en)	1996-02-21	1999-12-07	Hoescht Marion Roussel, Inc.	Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5922737A (en) *	1996-02-21	1999-07-13	Hoechst Marion Roussel, Inc.	Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5977139A (en) *	1996-12-15	1999-11-02	Hoechst Marion Roussel, Inc.	Carboxysubstituted cyclic carboxamide derivatives
CA2275527C (en) *	1996-12-19	2003-09-23	Hoechst Marion Roussel, Inc.	Novel heterocyclic substituted pyrrolidine amide derivatives
US5861417A (en) *	1996-12-19	1999-01-19	Hoechst Marion Roussel, Inc.	Heterocyclic substituted pyrrolidine amide derivatives
DE69706564T2 (de) *	1996-12-19	2002-07-11	Aventis Pharmaceuticals Inc., Bridgewater	Neue carboxy-substituierte cyclische carboxamidderivate
WO1998054191A1 (en)	1997-05-30	1998-12-03	Sankyo Company, Limited	Salts of optically active sulfoxide derivative
ID29137A (id) *	1998-07-27	2001-08-02	Schering Corp	Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
DK1246806T3 (da)	1999-11-03	2008-06-16	Amr Technology Inc	Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
MXPA03000275A (es)	2000-07-11	2004-12-13	Albany Molecular Res Inc	Nuevas tetrahidroisoquinolinas substituidas con 4-fenilo y su uso terapeutico.
DE60322423D1 (de) *	2002-12-13	2008-09-04	Smithkline Beecham Corp	Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
TW200524868A (en)	2003-07-31	2005-08-01	Zeria Pharm Co Ltd	Benzylamine derivatives
WO2005037269A1 (ja) *	2003-10-21	2005-04-28	Dainippon Sumitomo Pharma Co., Ltd.	新規ピペリジン誘導体
GB0412865D0 (en) *	2004-06-09	2004-07-14	Glaxo Group Ltd	Chemical compounds
UA91341C2 (ru)	2004-07-15	2010-07-26	Амр Текнолоджи, Інк.	Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
US7745427B2 (en) *	2004-10-22	2010-06-29	Merck Sharp & Dohme Corp.	CGRP receptor antagonists
CN104922117A (zh)	2005-03-22	2015-09-23	阿泽范药品公司	用于治疗月经前病症的β-内酰氨基链烷酸
ATE550019T1 (de)	2005-05-17	2012-04-15	Merck Sharp & Dohme	Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en)	2005-07-15	2011-06-07	Albany Molecular Research, Inc.	Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
CA2615813C (en)	2005-07-19	2015-12-15	Azevan Pharmaceuticals, Inc.	Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
AU2007300627B2 (en)	2006-09-22	2012-02-16	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh)	2006-11-30	2008-06-04	深圳市鼎兴生物医药技术开发有限公司	胆碱酯酶在拮抗速激肽药物中的应用
BRPI0806245B1 (pt)	2007-01-10	2022-01-25	Msd Italia S.R.L.	Compostos de fórmula i e seus usos
US8093268B2 (en)	2007-01-24	2012-01-10	Glaxo Group Limited	Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
WO2009002495A1 (en)	2007-06-27	2008-12-31	Merck & Co., Inc.	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en)	2008-03-03	2013-12-03	Tiger Pharmatech	Protein kinase inhibitors
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (en)	2009-04-01	2012-09-19	Merck Sharp & Dohme	HAMMER OF ACT ACTIVITY
JP5739415B2 (ja)	2009-05-12	2015-06-24	ブリストル−マイヤーズスクウィブカンパニー	（Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
ES2446971T3 (es)	2009-05-12	2014-03-11	Albany Molecular Research, Inc.	Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
CN102595902B (zh)	2009-05-12	2015-04-29	阿尔巴尼分子研究公司	7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
CA2777043C (en)	2009-10-14	2015-12-15	Schering Corporation	Substituted piperidines that increase p53 activity and the uses thereof
WO2011137012A1 (en)	2010-04-27	2011-11-03	Merck Sharp & Dohme Corp.	Prolylcarboxypeptidase inhibitors
EP2584903B1 (en)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Novel heterocyclic compounds as erk inhibitors
AU2011272738B2 (en)	2010-07-01	2015-08-20	Azevan Pharmaceuticals, Inc.	Methods for treating post traumatic stress disorder
CN103068980B (zh)	2010-08-02	2017-04-05	瑟纳治疗公司	使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru)	2010-08-17	2021-04-01	Сирна Терапьютикс, Инк.	ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en)	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazole derivatives useful as erk inhibitors
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en)	2010-12-21	2012-06-28	Schering Corporation	Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en)	2011-04-21	2012-10-26	Piramal Healthcare Limited	A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
EP3919620A1 (en)	2012-05-02	2021-12-08	Sirna Therapeutics, Inc.	Short interfering nucleic acid (sina) compositions
CA2882950A1 (en)	2012-09-28	2014-04-03	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
SMT201700595T1 (it)	2012-11-28	2018-03-08	Merck Sharp & Dohme	Composizioni e metodi per trattare il cancro
WO2014100065A1 (en)	2012-12-20	2014-06-26	Merck Sharp & Dohme Corp.	Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en)	2013-01-30	2014-08-07	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
BR112016022575A2 (pt)	2014-03-28	2017-08-15	Azevan Pharmaceuticals Inc	Composições e métodos para o tratamento de doenças neurodegenerativas
CN107849044B (zh) *	2015-07-03	2021-06-25	豪夫迈·罗氏有限公司	作为ddr1抑制剂的三氮杂-螺癸酮类化合物
US10975084B2 (en)	2016-10-12	2021-04-13	Merck Sharp & Dohme Corp.	KDM5 inhibitors
KR102790657B1 (ko)	2017-09-15	2025-04-02	아제반 파마슈티칼스, 인코퍼레이티드	뇌 손상을 치료하기 위한 조성물 및 방법
EP3706742B1 (en)	2017-11-08	2023-03-15	Merck Sharp & Dohme LLC	Prmt5 inhibitors
WO2019094312A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
CA3108388A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
WO2020033282A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
EP3833667B1 (en)	2018-08-07	2024-03-13	Merck Sharp & Dohme LLC	Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99320A (en) *	1990-09-05	1995-07-31	Sanofi Sa	Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2676055B1 (fr) *	1991-05-03	1993-09-03	Sanofi Elf	Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.

1994
- 1994-04-22 WO PCT/US1994/004498 patent/WO1994026735A1/en not_active Ceased
- 1994-04-22 CN CN94192362A patent/CN1081635C/zh not_active Expired - Fee Related
- 1994-04-22 AT AT94917898T patent/ATE158580T1/de not_active IP Right Cessation
- 1994-04-22 JP JP52545394A patent/JP3424174B2/ja not_active Expired - Fee Related
- 1994-04-22 ES ES94917898T patent/ES2110761T3/es not_active Expired - Lifetime
- 1994-04-22 CA CA002160462A patent/CA2160462C/en not_active Expired - Fee Related
- 1994-04-22 NZ NZ267209A patent/NZ267209A/en unknown
- 1994-04-22 DK DK94917898.2T patent/DK0696280T3/da active
- 1994-04-22 HU HU9503153A patent/HU224496B1/hu not_active IP Right Cessation
- 1994-04-22 EP EP94917898A patent/EP0696280B1/en not_active Expired - Lifetime
- 1994-04-22 DE DE69405862T patent/DE69405862T2/de not_active Expired - Lifetime
- 1994-04-22 AU AU69426/94A patent/AU678023B2/en not_active Ceased
- 1994-04-26 TW TW083103768A patent/TW281675B/zh active
- 1994-05-02 IL IL10949694A patent/IL109496A/xx not_active IP Right Cessation
- 1994-05-06 MX MX9403386A patent/MX9403386A/es unknown
1995
- 1995-11-02 FI FI955258A patent/FI113047B/fi not_active IP Right Cessation
- 1995-11-03 NO NO954400A patent/NO309144B1/no not_active IP Right Cessation
1997
- 1997-11-26 GR GR970403124T patent/GR3025475T3/el unknown

Also Published As

Publication number	Publication date
NO954400D0 (no)	1995-11-03
AU678023B2 (en)	1997-05-15
CA2160462A1 (en)	1994-11-24
ES2110761T3 (es)	1998-02-16
DE69405862D1 (de)	1997-10-30
NO309144B1 (no)	2000-12-18
HU224496B1 (hu)	2005-10-28
HUT74085A (en)	1996-11-28
NZ267209A (en)	1997-09-22
NO954400L (no)	1996-01-08
DE69405862T2 (de)	1998-01-15
CA2160462C (en)	1998-12-15
EP0696280B1 (en)	1997-09-24
ATE158580T1 (de)	1997-10-15
TW281675B (da)	1996-07-21
AU6942694A (en)	1994-12-12
FI955258L (fi)	1995-11-30
JPH09500361A (ja)	1997-01-14
GR3025475T3 (en)	1998-02-27
FI113047B (fi)	2004-02-27
IL109496A (en)	2000-07-26
WO1994026735A1 (en)	1994-11-24
HU9503153D0 (en)	1996-01-29
EP0696280A1 (en)	1996-02-14
FI955258A0 (fi)	1995-11-02
MX9403386A (es)	1995-01-31
IL109496A0 (en)	1994-08-26
CN1081635C (zh)	2002-03-27
JP3424174B2 (ja)	2003-07-07
CN1124961A (zh)	1996-06-19

Publication	Publication Date	Title
NO954400D0 (no)	1995-11-03	Substituerte pyrrolidin-3-yl-alkyl-piperidiner som er anvendbare som tachykininantagonister
BR9917080A (pt)	2002-03-12	Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
DK0889877T3 (da)	2001-10-01	Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
PT894084E (pt)	2002-11-29	Derivados de acido cinamico e sua utilizacao como antagonistas de integrina
ES2160949T3 (es)	2001-11-16	Derivados de fenilen-sulfonamida sustituidos en meta.
DK0891325T3 (da)	2002-05-21	Para-substituerede phenylpropansyrederivater som integrinantagonister
RU95101048A (ru)	1996-10-27	Производные пролинамида, фармкомпозиция на их основе
DE69713152D1 (de)	2002-07-11	Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
DK0726893T3 (da)	2000-05-29	Hidtil ukendte 4-piperidinyl-substituerede lactamer som neurokinon 2-receptor-antagonister til behandling af astma
ES2160640T3 (es)	2001-11-16	Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
EP0680328A1 (en)	1995-11-08	KETOCONAZOLE COMPOSITIONS FOR LOCAL USE.
NO950757L (no)	1995-04-27	Antitussiv
MY115662A (en)	2003-08-30	Novel compounds with analgesic effect
DK0733051T3 (da)	2000-04-03	Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
ES2175328T3 (es)	2002-11-16	Piperidonas como antagonistas de la taquiquinina.
UA41350C2 (uk)	2001-09-17	Похідна морфоліну або її фармацевтично прийнятна сіль та фармацевтична композиція на її основі
GEP20002271B (en)	2000-10-25	Bicyclic Tachykinins Antagonists, Pharmaceutical Composition on Its Basis and Their Use
RU95109891A (ru)	1997-02-10	19,11-перекрытые мостиками 4-эстрены, способ их получения, содержащая их фармацевтическая композиция и промежуточные соединения для их получения
RU94036762A (ru)	1996-09-10	Гетероарилпиперидины, способ их получения, промежуточные соединения синтеза и фармацевтическая композиция
UA37217C2 (uk)	2001-05-15	Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, фармацевтична композиція та проміжні сполуки
ES2065855B1 (es)	1995-09-01	Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
UY26971A1 (es)	2002-06-20	Nuevos antagonistas de neuroquinina, procedimiento para su preparación y composiciones farmacéuticas que contienen estos compuestos
RU93044977A (ru)	1996-06-20	Ароматические производные аминов и способ их получения
AR011169A1 (es)	2000-08-02	Compuestos derivados de quinoxalinadionas, su uso para la preparacion de medicamentos, compuestos intermediarios y procedimiento para preparar dichos medicamentos
IT8719564A0 (it)	1987-03-04	Piperazine asimmetriche adattivita' farmacologica, procedimento per la loro preparazione e compisizioni farmaceutiche relative.